Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) Research & Development (2016 - 2022)

Edesa Biotech's Research & Development history spans 10 years, with the latest figure at $1.8 million for Q3 2022.

  • For Q3 2022, Research & Development fell 56.54% year-over-year to $1.8 million; the TTM value through Sep 2022 reached $13.3 million, down 25.7%, while the annual FY2025 figure was $3.7 million, 27.3% up from the prior year.
  • Research & Development for Q3 2022 was $1.8 million at Edesa Biotech, down from $4.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.0 million in Q1 2021 and bottomed at $111702.0 in Q1 2019.
  • The 5-year median for Research & Development is $1.3 million (2020), against an average of $2.1 million.
  • The largest annual shift saw Research & Development tumbled 77.38% in 2019 before it soared 1486.13% in 2021.
  • A 5-year view of Research & Development shows it stood at $257391.0 in 2018, then surged by 105.13% to $527998.0 in 2019, then surged by 161.3% to $1.4 million in 2020, then soared by 186.38% to $4.0 million in 2021, then plummeted by 54.6% to $1.8 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Research & Development are $1.8 million (Q3 2022), $4.5 million (Q2 2022), and $3.0 million (Q1 2022).